Trailing-twelve-month (TTM) revenue is $808.21 Million with a year-over-year growth of +14.31%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $209,361,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q4 FY2025Period ended 2025-12-31 | $205,449,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-26 |
| Q1 FY2026Period ended 2026-03-31 | $193,520,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $199,878,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $808,208,000 |
Current P/S: $715,813,503 market capitalization ÷ $808,208,000 TTM revenue = 0.89x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T16:25:16.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $199.88M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T16:26:17.234Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Belbuca | N/A | N/A | $126M | $182M | $211M | $222M |
| Nucynta | $182M | N/A | N/A |
$808.21M
$808.21 Million
+14.31%
vs. $707.03M a year ago (TTM)
+19.91%
5 Year compound annual growth rate
1 Year
+14.31%
3 Year
+14.60%
5 Year
+19.91%
10 Year
N/A
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $780.57M | +$149.12M | +23.62% |
| 2024 | $631.45M | +$64.68M | +11.41% |
| 2023 | $566.77M | +$102.83M | +22.17% |
| 2022 | $463.93M | +$187.06M | +67.56% |
| 2021 | $276.87M | ($33.15M) | (10.69%) |
| 2020 |
TTM Growth
+14.31%
3-Year CAGR
+14.60%
5-Year CAGR
+19.91%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 32 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T16:26:17.234Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
| N/A |
| N/A |
| N/A |
| Nucynta Er | $66M | N/A | N/A | N/A | N/A | N/A |
|---|
| Nucynta ER | N/A | $71M | $72M | $83M | $76M | $81M |
|---|
| Nucynta Ir | $116M | N/A | N/A | N/A | N/A | N/A |
|---|
| Nucynta IR | N/A | $102M | $112M | $108M | $101M | $115M |
|---|
| Nucynta Products | N/A | $173M | N/A | N/A | N/A | N/A |
|---|
| Other | N/A | N/A | $2M | N/A | N/A | N/A |
|---|
| Symproic | N/A | N/A | $12M | $16M | $15M | N/A |
|---|
| Xtampza | $128M | N/A | N/A | N/A | N/A | N/A |
|---|
| Xtampza ER | N/A | $104M | $139M | $177M | $191M | $199M |
|---|
| $310.02M |
| +$13.31M |
| +4.49% |
| 2019 | $296.70M | +$16.29M | +5.81% |
| 2018 | $280.41M | +$251.94M | +884.73% |
| 2017 | $28.48M | +$26.77M | +1564.29% |
